HepaRegeniX: Funding, Investors & Team (Sep 2026)
HepaRegeniX is creating medications to treat acute and chronic liver diseases by restoring the regenerative ability of hepatocytes. This therapeutic method is based on research conducted by Professor Lars Zender's team at the University Hospital Tübingen, which identified MKK4 as a crucial factor in liver regeneration. The team found that suppressing the MKK4 gene through small RNA molecules could enhance the regenerative capaUK hepatocytes in diseased livers. Founded in 2015, HepaRegeniX is working on developing MKK4 inhibitors as a potential treatment for liver disorders, including nonalcoholic steatohepatitis.
HepaRegeniX has raised $24.3M across 1 funding round on record, the most recent an undisclosed round of $24.3M announced in Apr 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
HepaRegeniX Company Profile and Key Stats
Latest funding round on record: Apr 2025.
HepaRegeniX Funding Rounds
HepaRegeniX Founders and Leadership Team
Contact details for the HepaRegeniX team: 1 of 1 has an email address on file.
Start 14-day free trial →HepaRegeniX Funding Compared to Other Biotechnology Startups
HepaRegeniX's latest round of $24.3M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like HepaRegeniX in Biotechnology and Ulm
Companies Similar to HepaRegeniX
Computomics applies AI to bioinformatics data to enable rapid understanding of genomics and drive advanced…
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug…
Pacifico Biolabs offers fermentation biotechnology for development, production and distribution of…
NanoStruct is a biotechnology company that develops nanostructured sensor chips to identify bacteria and…
Tacalyx, a company originating from Max-Planck-Institute of Colloids and Interfaces in Potsdam, Germany, is…
Primogene is a biotechnology company that provides ingredient development, bioprocess manufacturing, and…
Mbiomics is a company in the field of biotechnology.
At EVANIUM, we make plant compounds like polyphenols and flavonoids more effective by improving their…
Picea Biosolutions is a biotechnology firm. Based on their core platform technology, they develop tailored…
KUPANDO is a pioneering biopharmaceutical firm that is developing TLR 4/7 agonists to boost innate immunity.…
HepaRegeniX Funding FAQs
What does HepaRegeniX do?
HepaRegeniX is creating medications to treat acute and chronic liver diseases by restoring the regenerative ability of hepatocytes. This therapeutic method is based on research conducted by Professor Lars Zender's team at the University Hospital Tübingen, which identified MKK4 as a crucial factor in liver regeneration. The team found that suppressing the MKK4 gene through small RNA molecules could enhance the regenerative capaUK hepatocytes in diseased livers. Founded in 2015, HepaRegeniX is working on developing MKK4 inhibitors as a potential treatment for liver disorders, including nonalcoholic steatohepatitis.
How much funding has HepaRegeniX raised?
HepaRegeniX has raised $24.3M across 1 round on record. The most recent is an undisclosed round of $24.3M announced in Apr 2025.
When did HepaRegeniX last raise funding?
HepaRegeniX's most recent funding round on record is an undisclosed round of $24.3M, announced in Apr 2025.
Who founded HepaRegeniX?
FundedIQ lists Wolfgang Albrecht (Founder) at HepaRegeniX.
Where is HepaRegeniX headquartered?
HepaRegeniX is based in Ulm, Baden-Wurttemberg, Germany.
How many employees does HepaRegeniX have?
HepaRegeniX is in the 11-50 employee band.
How does HepaRegeniX's funding compare to other Biotechnology startups?
HepaRegeniX's latest round of $24.3M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's HepaRegeniX Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for HepaRegeniX is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.